Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2020.05.039
Abstract: OBJECTIVE This study investigated the safety and tolerability of lifastuzumab vedotin (DNIB0600A) (LIFA), an antibody-drug conjugate, in patients with recurrent platinum-sensitive ovarian cancer (PSOC). METHODS In this open-label, multicenter phase 1b study, LIFA was administered… read more here.
Keywords: lifastuzumab vedotin; phase; vedotin dnib0600a; study ... See more keywords